Picture EBD Group Biotech Showcase 2023 San Francisco 650x100px
Document › Details

TrakCel Ltd.. (5/5/21). "Press Release: TrakCel Appoints Arturo Araya as Chief Commercial Officer". Cardiff.

Region Region United States (USA)
Organisations Organisation TrakCel (US)
  Group TrakCel (Group)
  Organisation 2 BrainStorm Cell Therapeutics Inc.
  Group BrainStorm (Group)
Products Product Ocellos by TrakCel
  Product 2 Kymriah®
Persons Person Araya, Arturo (TrakCel 202105– CCO based in US before Brainstorm Cell Therapeutics + Novartis + BMS)
  Person 2 Withey, Fiona (TrakCel 202002– CEO + Co-Founder before PCI Pharma Services + Biotec Services International)

> TrakCel appoints Chief Commercial Officer to drive adoption of new orchestration platform OCELLOS by TrakCel to cell and gene therapy sector

> Latest US hire brings more than two decades of international pharmaceutical experience to company C-Suite

TrakCel, a leading supplier of cellular orchestration solutions supporting the cell and gene therapy industry, today announces the appointment of Arturo Araya as Chief Commercial Officer.

“TrakCel has selected Arturo Araya for his high level of working knowledge within the cell and gene therapy field within organizations including Novartis, having played a large part in introducing Kymriah® to the market. He has been at the center of each evolutionary change of the supply chain, from birth through maturity. His market experience will enable him to provide invaluable input to TrakCel about industry requirements now and in the future, including how TrakCel can continue to develop its new second-generation cellular orchestration platform for the cell and gene therapy sector to deliver against those demands,” said Fiona Withey, Chief Executive Officer, TrakCel. “Arturo will be our sixth C-level representative at TrakCel, with an ideal spread in the US, and Europe, ensuring global coverage within TrakCel’s senior management. This also gives TrakCel’s C-level team a perfect blend of industry, product, development and commercial experience within the cell and gene therapy sector.”

Arturo’s immediate responsibility will be continuing to increase the adoption of OCELLOS by TrakCel, its new second-generation, Salesforce-powered cellular orchestration platform, to the cell and gene therapy sector. Specifically, his priority will be developing partnerships within both clinical and the largest commercial-scale organizations in the industry to continue to introduce OCELLOS by TrakCel into their value chains and existing systems.

“The cell and gene therapy industry has exponentially grown and matured since I worked on the first CAR-T. TrakCel’s central position within the sophisticated value chains of the CGT sector has enabled the company to impart its unrivaled knowledge of cellular orchestration into its new platform. This platform meets the varied needs of the majority of the CGT sector out of the box, with additional rapidly implementable tailoring available for the minority of specialists that have specific requirements,” said Arturo Araya, Chief Commercial Officer, TrakCel. “I have chosen to join TrakCel to help the industry democratize the development and supplying of transformative therapies to patients.”

Arturo Araya has over twenty five years’ experience within the biopharma and chemicals sector, and more than two decades of international pharmaceutical experience in the commercialization, marketing, and general management of pharmaceutical and cellular therapies. This includes leading a cross-functional team to commercialize a portfolio of cellular and gene therapies as Vice President and Head of Global Commercial for Novartis’s Cell and Gene Therapies Unit and included Kymriah®/CTL019, the first CAR-T approved by the US FDA. He also led the Oncology Unit for Novartis in seven countries. In addition to his work at Novartis, he also worked at Bristol-Myers Squibb in Marketing Intelligence, Business Development & Licensing. Most recently, Arturo has spent three years as EVP and Chief Commercial Officer of Brainstorm Cell Therapeutics Inc, preparing the commercialization of BCLI’s autologous MSC-based cell-therapy.


About TrakCel

TrakCel is a market leading developer of integrated technologies specifically created in 2012 to manage the international autologous and allogeneic cell, gene and immunotherapy supply chain. TrakCel’s software platform has been developed in collaboration with, and increasingly adopted by leading companies in the cell, gene and immunotherapy industries. TrakCel’s solutions deliver real-time control over the entire therapeutic supply chain, from sample collection through manufacturing to treatment delivery. The TrakCel platform accelerates global scale-up and scale-out of cell and gene therapy products, increasing efficiency and decreasing complexity, while maintaining treatment collection to administration compliance and traceability. TrakCel is headquartered in Cardiff, Wales, UK with US offices in California and New Jersey.

For more information contact:

Image Box PR
Neil Hunter / Michelle Boxall
Tel: +44 (0) 20 8943 4685 /

Record changed: 2022-02-05


Picture Wirtschaftsförderung Sachsen Life Sciences in Saxony 650x200px

More documents for TrakCel (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Campus Berlin-Buch GmbH BBC BerlinBioCube Start-up Center 650x300px

» top